Antibody-drug conjugates (ADCs) are regarded as a novel class of powerful therapeutic agents for cancer therapy, which consist of a monoclonal antibody (mAb) covalently bound with a cytotoxic drug through a chemical linker. mAb recognize antigens overexpressed on the surface of tumor cells, and cytotoxic payload is responsible for the execution of tumor cell killing.
There are no reviews for this PDF.
There are no comments for this PDF.
You must log in to post a comment.
Log in
